drugset
Drugs / Botulinum Toxins, Type A
last change May 2026 re-read 2 minutes ago

Botulinum Toxins, Type A

also known as Botox · Botulinum purified neurotoxin, Type A · Botulinum toxin A · botulinum toxin Type A · BTA · DWP-450 (Botulinum purified neurotoxin, Type A) Injection · DWP450 · NABOTA
Developed for
plantar fasciitis · urinary bladder disorder
Investigated by
Autonomous University of Nuevo León · Evolus, Inc. · Saskatchewan Health Authority - Regina Area

Trials 3 · a red edge is where a trial was stopped

today NCT03054610 · Ph 1 NCT02184988 · Ph 2 NCT01226706 · not/applicable
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03054610 Jan 2015 → Mar 2020 plantar fasciitis, salivary substance, Clostridium botulinum type Autonomous University of Nuevo León Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02184988 Aug 2014 → Dec 2015 — Evolus, Inc. Completed No outcome recorded
Phase not applicable1 trial
— NCT01226706 Jun 2008 → Sep 2010 urinary bladder disorder Saskatchewan Health Authority - Regina Area Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2026-05-19 Ipsen Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗
2021-02-10 AbbVie BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗
2020-07-09 AbbVie FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗
2020-06-22 AbbVie FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity abbvie.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Botulinum Toxins, Type A ClinicalTrials.gov intervention name — accepted as the source's own label NCT03054610 ↗
1

NCT01226706 ↗
Known as Botox “Botulinum toxin A (BTA or Botox©) may be a useful treatment in patients that do not respond to standard therapy.” NCT01226706 ↗
Known as Botulinum purified neurotoxin, Type A ClinicalTrials.gov intervention name — accepted as the source's own label NCT02184988 ↗
Known as Botulinum toxin A “Botulinum toxin A (BTA or Botox©) may be a useful treatment in patients that do not respond to standard therapy.” NCT01226706 ↗
Known as botulinum toxin Type A “followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.” NCT01226706 ↗
Known as BTA “Botulinum toxin A (BTA or Botox©) may be a useful treatment in patients that do not respond to standard therapy.” NCT01226706 ↗
Known as DWP-450 (Botulinum purified neurotoxin, Type A) Injection “DWP-450 (Botulinum purified neurotoxin, Type A) Injection” NCT02184988 ↗
Known as DWP450 “Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (onabotulinum toxin A).” PMID 26233808 ↗ Jul 2015
Known as NABOTA “Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (onabotulinum toxin A).” PMID 26233808 ↗ Jul 2015
Modality Protein / enzyme biologic “Biological: Botulinum purified neurotoxin, Type A” NCT02184988 ↗
Route Intramuscular “The subject is to be injected intra-muscularly into a total of five sites” NCT02184988 ↗